Osborne Clarke has advised iOnctura B.V. on the deal,iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has completed a €80 million Series B…
iOnctura B.V.’s €80 Million Series B Financing Round
Osborne Clarke has advised iOnctura B.V. on the deal,iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, has completed a €80 million Series B…